June 21, 2013

Efficacy of Sotrastaurin Plus Tacrolimus After De Novo Kidney Transplantation: Randomized, Phase II Trial Results


Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177
.   .   

New immunosuppressant agents face a high standard: theymust show comparable or superior results as current treatments with less side effects. Sotrastaurin is an oral medication that blocks protein kinase C to prevent T cell activation. In this randomized controlled trial, sotrastaurin combined with tacrolimus, steroids and basiliximab showed similar rates of acute rejection and graft function at 12 months as patients receiving tacrolimus, MPA, basiliximab and steroids. However, given the lack of improvement over the current standard of care, the manufacturer has decided not to proceed with further trials.

Renal Transplantation

Tags: , , , ,